Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers.
Karha, Juhana; Rajagopal, Vivek; Kottke-Marchant, Kandice; Bhatt, Deepak L.
Am Heart J
; 151(5): 976.e7-11, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16644316
A time-scaled convolution approach to construct IVIVC for enteric-coated acetylsalicylic acid tablets.
Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin.
Is enteric aspirin safer than regular aspirin?
Dissolution behavior of commercial enteric-coated aspirin tablets.
Evaluation of the pharmaceutical characteristics of various enteric-coated aspirin tablets under different storage conditions.
The role of food for the formation and prevention of gastrointestinal lesions induced by aspirin in cats.
[Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects].
Bioequivalence assessment of two enteric-coated aspirin brands, Nu-Seals and Loprin, after a single oral dose of 150 mg in healthy male adults.
Automated Dissolution for Enteric-Coated Aspirin Tablets: A Case Study for Method Transfer to a RoboDis II.
Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin.